RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating on Xenon Pharmaceuticals, maintaining a price target of $55.
September 03, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating on Xenon Pharmaceuticals, maintaining a price target of $55.
The reiteration of an Outperform rating and maintenance of a $55 price target by RBC Capital is a positive signal for Xenon Pharmaceuticals. This suggests confidence in the company's future performance and could lead to increased investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100